EGFR and breast cancer: Studies in the literature on the anti-cancer effects of EGFR inhibitor drugs related to breast cancer on MDA-MB-231 cells have reported IC50 concentrations of 20.7 μM for gefitinib, 42.6 μM for erlotinib, 15.4 μM for carboplatin, 59.6 nM for doxorubicin, and 3.0 nM for docetaxel [31].